Literature DB >> 24103586

A semiparametric approach to estimate rapid lung function decline in cystic fibrosis.

Rhonda D Szczesniak1, Gary L McPhail, Leo L Duan, Maurizio Macaluso, Raouf S Amin, John P Clancy.   

Abstract

PURPOSE: Detecting the onset of rapid lung function decline is important to reduce mortality rates in cystic fibrosis (CF) and other lung diseases. The most common approach is conventional linear mixed modeling-estimating a population-level slope of lung function decline and using random effects to address serial correlation-but this ignores nonlinear features of disease progression and distinct sources of variability. The purpose of this article was to estimate patient-specific timing and degree of rapid decline while appropriately characterizing natural progression and variation in CF.
METHODS: We propose longitudinal semiparametric mixed modeling and contrast it with the conventional approach, which restricts lung function (measured as forced expiratory volume in 1 second as a percentage of predicted, FEV1%) to linear decline. Each approach is applied to clinical encounter data from the United States CF Foundation Patient Registry.
RESULTS: Timing and degree of rapid FEV1% decline vary across patients and as a function of key covariates. Patients experience maximal FEV1% loss by early adulthood more severe than indicated by conventional slope analysis.
CONCLUSIONS: Semiparametric mixed modeling provides a means to estimate patient-specific changes in CF disease progression and may be used to inform prognostic decisions in chronic care settings and clinical studies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Epidemiologic methods; Nonlinear models; Spline regression

Mesh:

Year:  2013        PMID: 24103586     DOI: 10.1016/j.annepidem.2013.08.009

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  27 in total

1.  Joint hierarchical Gaussian process model with application to personalized prediction in medical monitoring.

Authors:  Leo L Duan; Xia Wang; John P Clancy; Rhonda D Szczesniak
Journal:  Stat (Int Stat Inst)       Date:  2018-03-04

2.  Early Detection of Rapid Cystic Fibrosis Disease Progression Tailored to Point of Care: A Proof-of-Principle Study.

Authors:  Rhonda Szczesniak; Cole Brokamp; Weiji Su; Gary L McPhail; John Pestian; John P Clancy
Journal:  Health Innov Point Care Conf       Date:  2017-12-21

3.  Semiparametric Mixed Models for Nested Repeated Measures Applied to Ambulatory Blood Pressure Monitoring Data.

Authors:  Rhonda D Szczesniak; Dan Li; Raouf S Amin
Journal:  J Mod Appl Stat Methods       Date:  2016

Review 4.  Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.

Authors:  Rhonda Szczesniak; Sonya L Heltshe; Sanja Stanojevic; Nicole Mayer-Hamblett
Journal:  J Cyst Fibros       Date:  2017-01-20       Impact factor: 5.482

5.  Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.

Authors:  Rhonda D Szczesniak; Dan Li; Weiji Su; Cole Brokamp; John Pestian; Michael Seid; John P Clancy
Journal:  Am J Respir Crit Care Med       Date:  2017-08-15       Impact factor: 21.405

6.  Bayesian Ensemble Trees (BET) for Clustering and Prediction in Heterogeneous Data.

Authors:  Leo L Duan; John P Clancy; Rhonda D Szczesniak
Journal:  J Comput Graph Stat       Date:  2016-08-05       Impact factor: 2.302

7.  Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline.

Authors:  William T Harris; J Todd Boyd; Gary L McPhail; Alan S Brody; Rhonda D Szczesniak; Leslie L Korbee; Michael L Baker; John P Clancy
Journal:  Ann Am Thorac Soc       Date:  2016-12

8.  Shared parameter models for joint analysis of longitudinal and survival data with left truncation due to delayed entry - Applications to cystic fibrosis.

Authors:  Mark D Schluchter; Annalisa V Piccorelli
Journal:  Stat Methods Med Res       Date:  2018-04-04       Impact factor: 3.021

9.  Predicting future lung function decline in cystic fibrosis patients: Statistical methods and clinical connections.

Authors:  Rhonda D Szczesniak; Gary L McPhail; Dan Li; Raouf S Amin; John P Clancy
Journal:  Pediatr Pulmonol       Date:  2015-12-17

10.  Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV1 decline.

Authors:  Don B Sanders; Zhanhai Li; Qianqian Zhao; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2017-07-29       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.